Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium
Authors
Keywords
-
Journal
Lancet HIV
Volume 9, Issue 7, Pages e474-e485
Publisher
Elsevier BV
Online
2022-06-08
DOI
10.1016/s2352-3018(22)00094-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
- (2022) Dathan M. Byonanebye et al. HIV MEDICINE
- Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
- (2021) Dathan M. Byonanebye AIDS
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
- (2021) Loveleen Bansi-Matharu et al. Lancet HIV
- Integrase Strand Transfer Inhibitors are associated with lower risk of incident Cardiovascular Disease in People Living with HIV
- (2020) Jane A. O’Halloran et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
- (2020) Willem D F Venter et al. Lancet HIV
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
- (2020) Alexandra Calmy et al. Lancet HIV
- The relationship between smoking, current CD4, viral load and cancer in persons living with HIV
- (2020) Amanda Mocroft AIDS
- Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
- (2018) Lene Ryom et al. Lancet HIV
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort
- (2018) Annegret Pelchen-Matthews et al. AIDS
- Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
- (2017) Adam Trickey et al. Lancet HIV
- An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
- (2015) Nina Friis-Møller et al. European Journal of Preventive Cardiology
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- No Association of Abacavir Use With Myocardial Infarction
- (2012) Xiao Ding et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Increased Platelet Reactivity in HIV-1–Infected Patients Receiving Abacavir-Containing Antiretroviral Therapy
- (2011) Claudette S. Satchell et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- (2010) Joseph J Eron et al. LANCET
- Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
- (2009) Signe Westring Worm et al. JOURNAL OF INFECTIOUS DISEASES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started